ClinicalTrials.gg
CompletedNCT06800170HP-phD_AdolescUpdated Oct 9, 2026

Treatment of Menstrual Cycle Alterations in Adolescents

An interventional study of myo-Inositol plus DIoscorea Villosa in Amenorrhea, Oligomenorrhea and PCOS (Polycystic Ovary Syndrome), sponsored by Lo.Li.Pharma s.r.l. Completed at 2 sites in 2 countries. Open to female participants aged 14 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Lo.Li.Pharma s.r.l · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
14 Years to 19 Years
Sex
Female
01

Study summary

the aim of the present study is intended to evaluate how treatment with Myo-Inositol and Dioscorea Villosa can help improve menstrual cycle irregularities in adolescents, both with and without PCOS.

Read the detailed description

The present study aims to evaluate the possible beneficial effect of a treatment with Inofolic HP combined with Inofolic phD on the improvement if menstrual cycle alteration in adolescent patients with or without PCOS.

The molecules chosen for the study are the following: myo-Inositol, α-lactalbumin, Dioscorea Villosa, and Vitamin D, are already commercialized as dietary supplements, commonly administered at same dosage provided in the present study, also for prolonged treatments, with no side effects associated.

02

Conditions studied

  • Amenorrhea
  • Oligomenorrhea
  • PCOS (Polycystic Ovary Syndrome)

Keywords

  • myo-Inositol
  • Dioscorea Villosa
  • adolescents
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's enrollment of 41 is below the median of 54 across 49 interventional studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

Lo.Li.Pharma s.r.l is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 19 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adolescent women aged 14-19 years old, with at least 3 years passed after menarche, and oligomenorrhea or amenorrhea

Exclusion criteria

Exclusion Criteria:

  • Primary amenorrhea.
  • Hyperandrogenism due to other factors (i.e. adrenal hyperplasia or Cushing syndrome).
  • Hyperprolactinemia or overt hypothyroidism (TSH ≥4).
  • Other hormonal alterations.
  • Ongoing hormonal therapies, including OCPs, six months before enrollment.
  • Ongoing pharmacological therapies.
  • Ongoing use of myo-Inositol supplement or other source of myo-Inositol, or Dioscorea villosa, six months before enrollment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Treated Group HP+phD

    Dietary Supplement: myo-Inositol plus DIoscorea Villosa

  • No intervention
    Controls

    Not treated patients

Interventions

  • Dietary supplementmyo-Inositol plus DIoscorea Villosa

    Drug page: InositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    myo-Inositol + alpha-lactalbumin + folic acid once daily, Dioscorea Villosa + alpha-lactalbumin + Vitamin D twice daily

    Also known as: myo-Inositol, Dioscorea Villosa

06

What researchers measure

Primary outcomes

  1. Menstrual cycle regularity

    The intervention is targed to adolescent patients suffering from menstrual cycle alterations. Particularly, we aim to asses the regularization of the menstrual cycle in those patients with polimenhorrea and oligo-/ amenorrhea, with irregular menstrual cycle (shorter than 21 days or longer than 35 days). The purpose of the study is to compare the percentage of patients exhibiting a regular menstrual cycle at the end of the treatment period, in the study group vs control.

    Time frame: 6 months

07

Study locations

2 sites
  • Zhordania and Khomasuridze Institute of Reproductology
    Tbilisi, Georgia 0112, Georgia
  • Department of Obstetrics and Gynecology with Reproductive Medicine, F.I. Inozemtsev Academy of Medical Education
    Saint Petersburg, Russian Federation, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Feb 2026, 8 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Apr 2026 → Feb 2026 and completion Jun 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 29, 2025
StartActual
Jun 1, 2025
Primary completionActual
Feb 2, 2026was Apr 2026
CompletionActual
Aug 2, 2026was Jun 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 30, 2026→Feb 2, 2026
Oct 9, 2026
Study completion
Jun 1, 2026→Aug 2, 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Apr 30, 2026→Feb 2, 2026
    Study completion Jun 1, 2026→Aug 2, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06800170
Lead sponsor
Lo.Li.Pharma s.r.l
Responsible party
Vittorio Unfer (Professor, AGUNCO Obstetrics and Gynecology Centre) — Principal investigator
First posted
Jan 29, 2025
Start date
Jun 1, 2025
Primary completion
Feb 2, 2026
Completion
Aug 2, 2026
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inositol

Start the discussion